Table 1.

Baseline Characteristics of 218 Included Patients who Achieved Complete Eradication of Intestinal Metaplasia (CE-IM) and had an additional surveillance examination.

Baseline Characteristic	All eligible patients (306) - N (%)	Patients with CE-IM (260) - N (%)	Patients with CE-IM in surveillance (218) - N (%)
Age (years)
- 25 to 60	53 (17.3)	44 (17.3)	36 (16.7)
- 61 to 80	194 (63.4)	168 (66.1)	145 (67.4)
- 81 to 101	52 (17.0)	42 (16.5)	34 (15.8)
- Mean [SD]	70.2 [11.2]	70.0 [11.0]	69.9 [10.4]
Low-grade dysplasia	98 (32.0)	84 (32.3)	75 (34.3)
High-grade dysplasia	188 (61.4)	158 (50.8)	128 (58.7)
Intramucosal adenocarcinoma	20 (6.5)	18 (6.9)	15 (6.9)
BMI (mg/kg2)
- Normal (18.5 – 24.9)	53 (17.5)	40 (15.6)	30 (13.9)
- Overweight (25.0 – 29.9)	119 (39.4)	108 (42.2)	96 (44.4)
- Obesity (>=30)	130 (43.0)	108 (42.2)	90 (41.7)
- Mean [SD]	29.9 [5.9]	30.0 [6.0]	30.0 [5.7]
Female	106 (34.6)	89 (34.2)	68 (31.2)
Male	200 (65.4)	171 (65.8)	150 (68.8)
No history of alcohol use	127 (42.8)	107 (42.5)	89 (42.0)
- Current alcohol use	134 (45.1)	115 (45.6)	96 (45.3)
- Past alcohol use	36 (12.1)	30 (11.9)	27 (12.7)
No history of tobacco use	131 (43.5)	117 (45.7)	104 (48.4)
- Current tobacco use	52 (17.3)	41 (16.0)	33 (15.3)
- Past tobacco use	118 (39.2)	98 (38.3)	78 (36.3)
Prague M length (cm)
- 0 to 3	119 (39.7)	108 (42.2)	89 (41.6)
- 4 or more	181 (60.3)	148 (57.8)	125 (58.4)
- Mean [SD]	5.0 [3.5]	4.6 [3.1]	4.6 [3.0]
Prague C length (cm)
- 0 to 3	262 (85.6)	230 (88.5)	194 (89.0)
- 4 or more	44 (14.4)	30 (11.5)	24 (11.0)
- Mean [SD]	3.7 [3.8]	3.0 [3.1]	3.2 [3.1]
GERD symptoms at diagnosis	123 (43.0)	109 (44.7)	91 (44.0)
- no GERD symptoms	163 (57.0)	135 (55.3)	116 (56.0)
ASA use	127 (41.8)	109 (42.1)	91 (44.0)
- no use	177 (58.2)	150 (57.9)	116 (56.0)
NSAID use	45 (14.8)	39 (15.1)	36 (16.6)
- no use	259 (85.2)	220 (84.9)	181 (83.4)
Nissen Fundoplication	15 (5.0)	13 (5.0)	12 (5.6)
- no Nissen	288 (95.5)	245 (95.0)	204 (94.4)

BMI, body mass index.